Arpita Maiti’s Post

The new #100DaysMission scorecard highlights the critical need for accelerated investment to develop safe and effective diagnostics, therapeutics, and vaccines to prepare for the next pandemic. Here is the link for the full report: https://lnkd.in/dDVph-DG Disease Prevention & Control Summit #pandemicpreparedness #infectiousdiseases #infectioncontrol

BREAKING NEWS: DIAUNION 2.0 IS NOW A REALITY! Supported by an unrestricted research grant of €3.9MM from Sanofi, we are now able to launch the next step of DiaUnion. The DiaUnion autoantibody screening 2.0 program is established to identifying people pre-symptomatic for type 1 diabetes and the related autoimmune diseases, celiac disease and autoimmune thyroid disease. The DiaUnion autoantibody screening 2.0 program is expected to find a total 7,030 aab positive individuals over the course of 3 years in Sweden and Denmark. Of these, 2,196 will be T1D aab positive, and 1,244 will have two or more T1D aabs (stage 1+2) within the 3 years of the program. The ambition of DiaUnion is to develop a model for establishment of permanent type 1 diabetes (and related autoimmune diseases) screening programs. DiaUnion 2.0 launches July 1, 2024. Press releases in Swedish and Danish attached. #type1diabetes #overgransen

Viral #hepatitis affects the lives of about one in twenty people in the world, resulting in over a million deaths each year. NIAID is working on many ways to prevent and treat the different types of hepatitis, including the development of vaccines and improved therapeutics and diagnostics. July 28 is observed annually as #WorldHepatitisDay, providing an opportunity to reflect on the impact of hepatitis on global health and focus on strategies to reduce its burden. To observe World Hepatitis Day, NIAID highlights recent advances researchers have made in these areas. Learn more at https://go.nih.gov/UpN6IiI

ACeD-it Study now enrolling! This phase 1b/2 clinical trial is testing the investigational treatment KAN-101 in adults with celiac disease. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens. This is called immune tolerance. This trial may be an option if you: - Are 18-70 years old - Have biopsy-confirmed celiac disease - Have been on a gluten-free diet for at least the last 12 months You may be compensated for time and travel. Learn more and see if you qualify: Anokion.com/ACeD-it

Want to expand your knowledge on the role of the complement system in infectious disease? Take a deep dive into the power of the complement system and how a better understanding can help improve diagnosis, therapy, and prevention of infectious disease by targeting this system more effectively. Read this new Editorial article https://hubs.ly/Q02dy-TW0 to explore this essential role of the complement system in infectious disease! #DrugDiscovery #Pharma #Therapeutics #complementsystem #answersinlifescience #expertpartner #partnerwithus #infectiousdisease

ACeD-it Study now enrolling! This phase 1b/2 clinical trial is testing the investigational treatment KAN-101 in adults with celiac disease. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens. This is called immune tolerance. This trial may be an option if you: - Are 18-70 years old - Have biopsy-confirmed celiac disease - Have been on a gluten-free diet for at least the last 12 months You may be compensated for time and travel. Learn more and see if you qualify: Anokion.com/ACeD-it

SynCeD Study now enrolling! This phase 2a clinical trial is testing the investigational treatment KAN-101 in adults with celiac disease. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens. This is called immune tolerance. This trial may be an option if you: - Are 18-70 years old - Have biopsy-confirmed celiac disease - Have been on a gluten-free diet for at least the last 12 months You may be compensated for time and travel. Learn more: Anokion.com/SynCeD See if you qualify: https://lnkd.in/gtdKfb-c

Applying global proteomics analysis to your in vivo pharmacology models adds another dimension to your data and gets the most out of your investment in time and money. Also, translation and portability into the clinic add further value.

Rare Disease Day 2024: Sharing Our Colours with XTMAB-16 Today, on Rare Disease Day, we at Xentria want to reiterate our unwavering commitment to making a difference in the lives of those affected by rare diseases. At the core of our mission is the development of our investigational medication, XTMAB-16, designed to address the challenges experienced by individuals dealing with a rare condition like pulmonary sarcoidosis.  This day serves as a global reminder of the 300 million individuals and their families who navigate the complexities of rare diseases every day. We recognize the profound impact of rare diseases, and this understanding propels us to prioritize patient-focused drug development.  We want to increase opportunity to innovative solutions for those with rare diseases, supporting a pathway to receive the care and support they deserve. This includes providing valuable information about clinical trials, like the Phase II trial for XTMAB-16, a monoclonal antibody targeting the inflammatory response believed to occur in sarcoidosis. We are actively enrolling patients for this trial and have the following sites open: https://lnkd.in/g5D-bdp4. To learn more about our work, sarcoidosis, the XTMAB-16 trial, please visit www.xentria.com. Let’s unite in “Sharing Our Colours” this Rare Disease Day, working together to create a brighter future for those affected by rare diseases.  #rarediseaseday2024 #rarediseaseday #shareyourcolours #sarcoidosis

As you may have heard by now, the FDA is continuing to take steps to advance treatments for rare disease. The CBER and CDER together have initiated the START Pilot Program which allows chosen companies with rare disease treatment options to have easier access to FDA support, guidance, and initiatives. Among the rare diseases being studied are: Friedrich's ataxia, Vanishing White Matter disease, Sanfilippo syndrome, NGLY1 Deficiency, Isolated methylmalonic acidemia, Canavan Disease, and Rett Syndrome. We are looking forward to seeing the progress made through the START Pilot Program! #clinicalresearch #innovation #FDA #STARTpilotprogram #gsclinical